Copy

CERUS E-NEWS SPECIAL EDITION :
Industry Workshop at CBBS/SCABB Joint Meeting 2018


We invite you to join us at the following events during the upcoming CBBS/SCABB Joint Meeting
(California Blood Bank Society / South Central Association of Blood Banks)
in Glendale/Phoenix, Arizona, April 24-28




Cerus Industry Workshop Oral Presentations featuring Pathogen Reduction 
Cerus Booth at the Exhibit Hall
Cerus Industry Workshop at CBBS/SCABB Joint Meeting Phoenix, AZ:
 

Pathogen Reduced Platelets: Expanding Supply and Patient Access

   
    
Wednesday April 25, 2018
    1:30pm – 2:30pm
    Room: Cira C
    Renaissance Hotel | Glendale AZ

Platelet safety and availability continue to be of concern for blood suppliers and hospitals, particularly in light of the FDA draft guidance on bacterial contamination. While pathogen reduction plays a pivotal role in improving platelet safety, challenges have been expressed regarding the sufficient production capacity of pathogen reduced platelets to meet hospital needs. The first part of this symposium will provide an overview of methods used by blood centers to increase production compatibility with the INTERCEPT Blood System requirements while maintaining overall split rate. The second part of this symposium will review hospital transfusion services considerations for safe blood products in the context of quality initiative programs. Reduction of the risks associated with platelet transfusion may help hospitals minimize occurrences of hospital-acquired infections (HAIs) and re-admissions thereby improving patient outcomes and minimizing negative financial impact.
 

Presented by:

Beau J. Robertson, MPH, MLS(ASCP),CQA(ASQ), Associate Deployment Director, Cerus Corporation
Cynthia Robbins, RPH BSPHARM, Sr. Director, Hospital Affairs, Cerus Corporation
Pathogen Reduction Orals
Two oral presentations related to availability and economics of the INTERCEPT Blood System will be presented at the CBBS/SCABB meeting.
  • Cost Implications of Pathogen Reduced Platelets: A Hospital Budget Impact Model (Prioli KM, Lyons NM, Karp JK, Herman JH, Pizzi LT, Robbins C, Chrebtow V)

  • Increasing Compatibility of Apheresis Platelet Collections with Pathogen Reduction While Maintaining Current Split Rates (Weiner E, Chrebtow V)

Cerus Exhibit Booth
The Cerus / INTERCEPT Booth #36 will be located in the main exhibition area.
 
2018 Calendar of Events

ASPHO/PBMTC Annual Meeting (American Society of Pediatric Hematology/Oncology)
May 2-5, 2018 | Pittsburgh, PA

ISBT International Congress / CSTM (International Society of Blood Transfusion)
June 2-6, 2018 | Toronto, Canada

SABM (Society for the Advancement of Blood Management)
Sept 13-15, 2018 | New York, NY

AABB Annual Meeting (Association of Blood Banks)
Oct 13-16, 2018 | Boston, MA

ASA Annual Meeting (American Society of Anesthesiologists)
Oct 13-17, 2018 | San Francisco, CA

ASH Annual Meeting (American Society of Hematology)
Dec 1-4, 2018 | San Diego, CA
Rx only. There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

CONTRAINDICATIONS: Contraindicated for preparation of plasma and platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet and plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS and PRECAUTIONS: Only INTERCEPT Processing Sets for platelets and plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet and plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl) phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLATELETS: INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.


PLASMA: Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

INTERCEPT Blood System for Red Blood Cells is in development and not available for sale.


For full prescribing information, please see package insert.
MKT-EN 00165-28
Copyright © 2018 Cerus Corporation, All rights reserved.
Cerus, INTERCEPT Blood System and INTERCEPT are registered trademarks of Cerus Corporation.

Our mailing address is:
Cerus Corporation
2550 Stanwell Drive
Concord, CA 94520

Add us to your address book


unsubscribe from this list    update subscription preferences